A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naive Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Alexion Pharmaceuticals, Inc.
Start Date
March 24, 2017
End Date
October 17, 2017
Administered By
Duke Cancer Institute
Awarded By
Alexion Pharmaceuticals, Inc.
Start Date
March 24, 2017
End Date
October 17, 2017